Thermo Fisher Scientific has expanded access to the Oncomine™ Comprehensive Assay Plus by enabling its use on the Ion Torrent™ Genexus™ System, supporting more rapid and automated comprehensive genomic profiling in oncology research.
The Oncomine Comprehensive Assay Plus is designed to detect a wide range of genomic alterations across 517 genes, including single-nucleotide variants, insertions and deletions, copy number variations, and gene fusions. The assay also supports analysis of key genomic signatures such as homologous recombination deficiency, tumor mutational burden, and microsatellite instability.
Previously available on the Ion GeneStudio™ S5 platforms, the assay is now integrated with the Genexus System, which provides an automated end-to-end workflow from sample preparation to data analysis. The system is capable of delivering results within approximately 24 hours, reducing the time and labor typically required for NGS-based CGP.
The integration of this assay on an automated platform may enable broader adoption of CGP across research environments with varying levels of technical expertise. According to early-access users, such as Hector M. Alcaraz, MS, of Imagene Health, SA de CV, the expanded biomarker coverage and reduced turnaround time may enhance accessibility to CGP in resource-limited settings.
The Genexus System’s automated workflow is intended to streamline sample handling and data interpretation, potentially reducing variability and supporting more consistent results across laboratories.